News
Important Only
Boardwalk REIT Provides Operational Update
July 7 (Reuters) - Boardwalk Real Estate Investment Trust BEI_u.TO:BOARDWALK REIT PROVIDES OPERATIONAL UPDATE, REPORTS ADVANCEMENT OF CAPITAL UPCYCLING INITIATIVES AND ANNOUNCES TIMING OF SECOND QUARTER RESULTSFurther company coverage: [BEI_u.TO]Reuters
Mon, Jul 7
NWTN Inc. Announces Key Executive Appointments To Accelerate Strategic Transformation
July 7 (Reuters) - NWTN Inc NWTN.O:NWTN INC. ANNOUNCES KEY EXECUTIVE APPOINTMENTS TO ACCELERATE STRATEGIC TRANSFORMATIONNWTN INC - APPOINTS ADRIAN WONG AS CFO AND JOHN XIE AS COONWTN INC - BENJAMIN ZHAI APPOINTED AS GLOBAL CEO ON MAY 13, 2025Reuters
Mon, Jul 7
Quidelortho Strengthens Leadership Team With Appointments Of Senior Vice Presidents For Global Quality And Clinical & Regulatory Affairs
July 7 (Reuters) - Quidelortho Corp QDEL.O:QUIDELORTHO STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENTS OF SENIOR VICE PRESIDENTS FOR GLOBAL QUALITY AND CLINICAL & REGULATORY AFFAIRSReuters
Mon, Jul 7
Santacruz Silver Announces Payment To Glencore Of US$7.5 Million Under Acceleration Plan
July 7 (Reuters) - Glencore PLC GLEN.L:SANTACRUZ SILVER ANNOUNCES PAYMENT TO GLENCORE OF US$7.5 MILLION UNDER ACCELERATION PLANSANTACRUZ SILVER MINING LTD - PLAN EXPECTED TO GENERATE US$40 MILLION IN SAVINGSReuters
Mon, Jul 7
Boston Scientific Receives FDA Approval For Expanded Labeling Of Farapulse™ Pulsed Field Ablation System
July 7 (Reuters) - Boston Scientific Corp BSX.N:BOSTON SCIENTIFIC RECEIVES FDA APPROVAL FOR EXPANDED LABELING OF FARAPULSE™ PULSED FIELD ABLATION SYSTEMBOSTON SCIENTIFIC CORP: ANTICIPATES CE MARK & APPROVAL IN JAPAN AND CHINA IN COMING MONTHSReuters
Mon, Jul 7
Blackrock To Acquire Elmtree Funds
July 7 (Reuters) - BlackRock Inc BLK.N:BLACKROCK TO ACQUIRE ELMTREE FUNDSBLACKROCK: ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSEDBLACKROCK INC - ELMTREE FUNDS HAS $7.3 BILLION IN ASSETS UNDER MANAGEMENTBLACKROCK INC - CONSIDERATION PAID IN STOCK, ADDITIONAL BASED ON PERFORMANCEBLACKROCK INC - ELMT...Reuters
Mon, Jul 7
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY
July 7 (Reuters) - Kalvista Pharmaceuticals Inc KALV.O:KALVISTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF EKTERLY® (SEBETRALSTAT), FIRST AND ONLY ORAL ON-DEMAND TREATMENT FOR HEREDITARY ANGIOEDEMAKALVISTA PHARMACEUTICALS INC - LAUNCHES EKTERLY IN U.S., PRESCRIPTIONS AVAILABLEReuters
Mon, Jul 7
Molina Healthcare Announces Preliminary Q2 Financial Results
July 7 (Reuters) - Molina Healthcare Inc MOH.N:MOLINA HEALTHCARE ANNOUNCES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS AND UPDATES FISCAL YEAR 2025 EARNINGS PER SHARE GUIDANCEEXPECTS Q2 2025 EARNINGS OF $5.50 PER SHAREEXPECTS 2025 ADJUSTED EARNINGS OF $21.50-$22.50 PER SHAREQ2 EARNINGS PER SHARE VI...Reuters
Mon, Jul 7
Molina Healthcare Expects 2025 Adjusted EPS Of $21.50-$22.50
July 7 (Reuters) - Molina Healthcare Inc MOH.N:MOLINA HEALTHCARE ANNOUNCES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS AND UPDATES FISCAL YEAR 2025 EARNINGS PER SHARE GUIDANCEEXPECTS Q2 2025 ADJUSTED EARNINGS OF $5.50 PER SHARE EXPECTS 2025 ADJUSTED EARNINGS OF $21.50-$22.50 PER SHAREQ2 EARNINGS PE...Reuters
Mon, Jul 7
Demand for obesity drugs shoots up in India as Lilly, Novo jostle for market share
By Rishika Sadam HYDERABAD, July 7 (Reuters) - Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly LLY.N and Novo Nordisk NOVOb.CO are competing for market share, data from research firm Pharmarack showed on Monday.Sales of Lilly's Mounjaro, which launched in...Reuters
Mon, Jul 7
Molina Healthcare lowers annual profit forecast on medical cost pressures
July 7 (Reuters) - Molina Healthcare MOH.N on Monday lowered its annual adjusted profit forecast due to medical cost pressures.The company now sees adjusted profit per share to be between $21.50 and $22.50, compared with at least $24.50 per share expected previously.Reuters
Mon, Jul 7
